VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

VJVirtual | Checkpoint blockade in PS2 NSCLC patients

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the results of the Checkmate 171 (NCT02409368) and PePS2 (NCT02733159) studies which have highlighted a significant benefit of checkpoint blockade therapy for advanced non-small cell lung cancer (NSCLC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter